Drug Markets/Chlorothiazide

Chlorothiazide

1 NDC across 1 manufacturer|0 Generic,1 Brand

Chlorothiazide is used to treat edema, glomerulonephritis, heart failure, hypertension, liver cirrhosis and nephrotic syndrome, per the National Library of Medicine's MED-RT classification.

▸ More about this market

The brand product was first FDA-approved before 1982, and the first generic was approved Jan 1, 1982. In 2024, Medicare Part D spent $21K on Chlorothiazide across 236 claims for 85 beneficiaries.

Chlorothiazide is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $0.28 to $0.28 per ML. Every pack size and labeler in this drug market is compared side-by-side below.

Total NDCs

1

0G / 1B

Manufacturers

1

competing in market

Price Spread

$0.28 – $0.28

per ML

7d Activity

1 flat

avg +0.0% WoW · of 1 NDCs

Market Price Trend

Monthly average NADAC per unit, split by generic and brand.

Manufacturer Breakdown

1 manufacturer producing CHLOROTHIAZIDE

Drug Portfolio

1 NDCs total, 1 shown

Drug Price 7d Change
DIURIL 250 MG/5 ML ORAL SUSP
$0.2787
per ML

Frequently Asked Questions

What is Chlorothiazide used to treat?

Chlorothiazide is used to treat edema, glomerulonephritis, heart failure, hypertension, liver cirrhosis and nephrotic syndrome, per the National Library of Medicine's MED-RT classification.

When did Chlorothiazide become available as a generic?

FDA approved the first generic Chlorothiazide (ANDA) on Jan 1, 1982.

How much does Medicare spend on Chlorothiazide?

In 2024, Medicare Part D spent $21K on Chlorothiazide across 236 claims for 85 beneficiaries.

How many Chlorothiazide products are on the market?

The Chlorothiazide drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.

What is the price range for Chlorothiazide?

NADAC reference prices for Chlorothiazide range from $0.2787 to $0.2787 per ML.

Which manufacturers make Chlorothiazide?

1 manufacturer lists Chlorothiazide in NADAC. Ranked by number of NDCs, the largest are Salix Pharmaceuticals Inc. (1).